Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal
Covers Novel Cancer Immunotherapy Targets And Therapies
Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.
